NCT03728361 - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2018

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

Grade I Neuroendocrine CarcinomaGrade II Neuroendocrine CarcinomaGrade III Neuroendocrine CarcinomaMetastatic Neuroendocrine CarcinomaNeuroendocrine CarcinomaRecurrent Small Cell Lung CarcinomaRefractory Small Cell Lung CarcinomaLung Cancer Stage IVLarge Cell Neuroendocrine CarcinomaNeuroendocrine TumorsSmall Cell Lung Cancer MetastaticSmall-cell Lung Cancer

Interventions

BIOLOGICAL

Nivolumab

Given IV

DRUG

Temozolomide

Given PO

Trial Locations (2)

43210

Ohio State University Comprehensive Cancer Center-COHORT 1, Columbus

Ohio State University Comprehensive Cancer Center-COHORT 2, Columbus